Jonathan W. Goldman, MD

Jonathan W. Goldman, MD, health sciences clinical instructor, Department of Medicine, and Hematology/Oncology member, Jonsson Comprehensive Cancer Center Signal Transduction and Therapeutics Program, UCLA, discusses targeted therapy options for patients with 

-mutated non—small cell lung cancer (NSCLC).

In April 2018, osimertinib (Tagrisso) was approved by the FDA for the first-line treatment of patients with metastatic NSCLC whose tumors harbor 

 exon 19 deletions or exon 21 L858R mutations.

Osimertinib is a highly effective oral TKI with limited adverse events, explains Goldman.

Similarly, alectinib (Alecensa) is a well-tolerated oral TKI that was approved by the FDA in November 2017 for the treatment of patients with 

Patients treated with alectinib can experience durable remissions, says Goldman.

 mutations are relatively rare, 2 oral inhibitors, crizotinib (Xalkori) and entrectinib (Rozlytrek), have been approved for the treatment of patients with 

Videos

Jonathan W. Goldman, MD, discusses targeted therapy options for patients with EGFR-, ALK-, and ROS1-mutated non–small cell lung cancer.

Jonathan W. Goldman, MD

Articles

Dr. Goldman on Targeted Therapy Options for EGFR-, ALK-, and ROS1-Mutated NSCLC